Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway

Compared to single gemcitabine treatment, the combination of gemcitabine and erlotinib has shown effective response in patients with locally advanced or metastatic pancreatic cancer. However, the combination therapy has not proven effective in patients with pancreatic cancer after R0 or R1 resection...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liwen, Zhou, Ding'An, Liu, Zhehao, Huang, Xinhao, Liu, Qianfan, Kang, Yiping, Chen, Zili, Guo, Yuntao, Zhu, Haitao, Sun, Chengyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802029/
https://www.ncbi.nlm.nih.gov/pubmed/29328487
http://dx.doi.org/10.3892/or.2018.6198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802029/
https://www.ncbi.nlm.nih.gov/pubmed/29328487
http://dx.doi.org/10.3892/or.2018.6198

Ejemplares similares